Charles Harwood
Chairman en ACP Mountain Holdings, Inc. .
Perfil
Charles C.
Harwood is currently the Chairman of ACP Mountain Holdings, Inc. and an Operating Executive at Avista Capital Holdings LP.
He was previously the Chairman, President & CEO of BioReliance Corp., President & CEO of Quest Diagnostics Infectious Disease, Inc., CEO of MPI Research, Inc., President & CEO of BioReliance Holdings, Inc., Chairman of United BioSource Corp., Chairman of Inform Diagnostics, Inc., Director of Cellectar, Inc., Principal at HP, Inc., and CFO & Senior VP of Labcorp Drug Development, Inc. He holds an undergraduate degree from Stanford University and an MBA from Harvard Business School.
Cargos activos de Charles Harwood
Empresas | Cargo | Inicio |
---|---|---|
ACP Mountain Holdings, Inc.
ACP Mountain Holdings, Inc. Financial ConglomeratesFinance ACP Mountain Holdings, Inc. functions as an investment holding private company. The company is based in Wilmington, DE. | Chairman | - |
Avista Capital Holdings LP
Avista Capital Holdings LP Investment ManagersFinance Avista Capital Holdings LP (Avista Capital Partners) is a private equity firm founded in 2005 by Steven Webster and Thompson Dean. The firm is headquartered in New York. | Private Equity Investor | 01/01/2007 |
Antiguos cargos conocidos de Charles Harwood.
Empresas | Cargo | Fin |
---|---|---|
INC Research Holdings, Inc.
INC Research Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services INC Research Holdings, Inc. engages in the clinical research on therapeutic alignment and expertise in Central Nervous System, Oncology, and other complex diseases. It operates through the Clinical Development Services and Phase I Services segments. The Clinical Development Services segments offers a variety of select and stand-alone clinical development services such as clinical monitoring, investigator recruitment, patient recruitment, data management and study reports to assist customers with their drug development process. The Phase I Services segment focuses on clinical development services for Phase I trials that include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds. The company was founded on August 13, 2010 and is headquartered in Raleigh, NC. | Director/Board Member | 04/11/2016 |
BioReliance Corp.
BioReliance Corp. Pharmaceuticals: MajorHealth Technology BioReliance Corp. provides testing and manufacturing services to pharmaceutical and biopharmaceutical companies. It provides outsourced services to customers from most healthcare disciplines, including pharmaceutical, biopharmaceutical and chemical companies in the world. The firm also provides safety testing services focused on the rapidly growing biologics sector of the pharmaceutical and biotechnology industries. The company enables emerging and clinical stage companies who may lack the staff, expertise and financial resources to conduct many aspects of product development in-house. BioReliance was founded by Charles E. Bender in 1947 and is headquartered in Rockville, MD. | Chairman | 01/03/2013 |
BioReliance Holdings, Inc. | Chief Executive Officer | 01/03/2013 |
Cellectar, Inc.
Cellectar, Inc. Miscellaneous Commercial ServicesCommercial Services Cellectar, Inc. is a clinical stage radiopharmaceutical company that designs and develops products to detect, treat and monitor a wide variety of human cancers. Cellectar began independent lab activities in February 2003 after forming a company and raising initial funds in the 2000-2002 timeframe. Its product candidates combine phospholipids ethers analogs (PLEs), which are lipid-like molecules, with radioisotopes that destroy or image malignant cancer cells. Because only malignant tumor cells and tissues retain large amounts of these compounds, malignant cancer-selective retention of therapeutic or diagnostic doses of radioactivity can be achieved. Cellectar has demonstrated specific uptake and retention of its product candidates in more than 45 tumor types tested in proof-of-principle preclinical animal studies. In addition, ten preclinical experiments have shown anti-tumor activity in each tumor type studied including breast, prostate, lung, glioma, pancreatic, melanoma, ovarian, uterine, renal and colorectal cancers. The compound, originally known as NM404, is being taken through the regulatory process as CLR1404. Capitalizing on the unique characteristics of malignant cancer cells, Cellectar's molecules will be designed to find, treat and follow malignancies through the delivery of radiopharmaceuticals in a novel, highly selective way. | Director/Board Member | 01/04/2011 |
Quest Diagnostics Infectious Disease, Inc.
Quest Diagnostics Infectious Disease, Inc. Miscellaneous Commercial ServicesCommercial Services Quest Diagnostics Infectious Disease, Inc. provides diagnostic services. It offers anti infective surveillance and consultative services to the diagnosis, treatment, and management of infectious diseases. The company was founded in 1978 and is headquartered in Cypress, CA. | Chief Executive Officer | 01/07/2006 |
Formación de Charles Harwood.
Stanford University | Undergraduate Degree |
Harvard Business School | Masters Business Admin |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
HP INC. | Electronic Technology |
Empresas privadas | 13 |
---|---|
Labcorp Drug Development, Inc.
Labcorp Drug Development, Inc. Pharmaceuticals: MajorHealth Technology Covance, Inc. operates as a contract research organization and drug development company. Its services include research, lead optimization, analysis services, safety assessment and drug safety testing, consulting and partnering, clinical development, informatics, clinical testing, commercialization, and manufacturing support. The company was founded on November 12, 1996 and is headquartered in Princeton, NJ. | Health Technology |
BioReliance Corp.
BioReliance Corp. Pharmaceuticals: MajorHealth Technology BioReliance Corp. provides testing and manufacturing services to pharmaceutical and biopharmaceutical companies. It provides outsourced services to customers from most healthcare disciplines, including pharmaceutical, biopharmaceutical and chemical companies in the world. The firm also provides safety testing services focused on the rapidly growing biologics sector of the pharmaceutical and biotechnology industries. The company enables emerging and clinical stage companies who may lack the staff, expertise and financial resources to conduct many aspects of product development in-house. BioReliance was founded by Charles E. Bender in 1947 and is headquartered in Rockville, MD. | Health Technology |
United BioSource Corp.
United BioSource Corp. Miscellaneous Commercial ServicesCommercial Services United BioSource Corp. is a scientific and medical affairs organization that partners with life science companies to develop and commercialize their products. The company is involved in pre- and post-approval product development; pricing, coverage, reimbursement, and access strategies; and medical publication and communications. United BioSource Corp. was founded by Ethan D. Leder and Mark P. Cleinin in 2003 and is headquartered in Chevy Chase, MD. | Commercial Services |
Quest Diagnostics Infectious Disease, Inc.
Quest Diagnostics Infectious Disease, Inc. Miscellaneous Commercial ServicesCommercial Services Quest Diagnostics Infectious Disease, Inc. provides diagnostic services. It offers anti infective surveillance and consultative services to the diagnosis, treatment, and management of infectious diseases. The company was founded in 1978 and is headquartered in Cypress, CA. | Commercial Services |
MPI Research, Inc.
MPI Research, Inc. Miscellaneous Commercial ServicesCommercial Services MPI Research, Inc. provides preclinical research and development services. It offers drug safety, discovery sciences, bio-analytical and analytical solutions, surgical services, medical device evaluation, and specialty services. The company was founded by William U. Parfet in 1995 and is headquartered in Mattawan, MI. | Commercial Services |
Inform Diagnostics, Inc.
Inform Diagnostics, Inc. Hospital/Nursing ManagementHealth Services Inform Diagnostics, Inc. provides pathology diagnostic services. It offers subspecialty anatomic pathology in the fields of breast health, dermatology, gastroenterology, hematology, and urology. The company was founded by David D. Halbert and Harold Roe in 1996 and is headquartered in Irving, TX. | Health Services |
Avista Capital Holdings LP
Avista Capital Holdings LP Investment ManagersFinance Avista Capital Holdings LP (Avista Capital Partners) is a private equity firm founded in 2005 by Steven Webster and Thompson Dean. The firm is headquartered in New York. | Finance |
Cellectar, Inc.
Cellectar, Inc. Miscellaneous Commercial ServicesCommercial Services Cellectar, Inc. is a clinical stage radiopharmaceutical company that designs and develops products to detect, treat and monitor a wide variety of human cancers. Cellectar began independent lab activities in February 2003 after forming a company and raising initial funds in the 2000-2002 timeframe. Its product candidates combine phospholipids ethers analogs (PLEs), which are lipid-like molecules, with radioisotopes that destroy or image malignant cancer cells. Because only malignant tumor cells and tissues retain large amounts of these compounds, malignant cancer-selective retention of therapeutic or diagnostic doses of radioactivity can be achieved. Cellectar has demonstrated specific uptake and retention of its product candidates in more than 45 tumor types tested in proof-of-principle preclinical animal studies. In addition, ten preclinical experiments have shown anti-tumor activity in each tumor type studied including breast, prostate, lung, glioma, pancreatic, melanoma, ovarian, uterine, renal and colorectal cancers. The compound, originally known as NM404, is being taken through the regulatory process as CLR1404. Capitalizing on the unique characteristics of malignant cancer cells, Cellectar's molecules will be designed to find, treat and follow malignancies through the delivery of radiopharmaceuticals in a novel, highly selective way. | Commercial Services |
BioReliance Holdings, Inc. | Miscellaneous |
INC Research Holdings, Inc.
INC Research Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services INC Research Holdings, Inc. engages in the clinical research on therapeutic alignment and expertise in Central Nervous System, Oncology, and other complex diseases. It operates through the Clinical Development Services and Phase I Services segments. The Clinical Development Services segments offers a variety of select and stand-alone clinical development services such as clinical monitoring, investigator recruitment, patient recruitment, data management and study reports to assist customers with their drug development process. The Phase I Services segment focuses on clinical development services for Phase I trials that include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds. The company was founded on August 13, 2010 and is headquartered in Raleigh, NC. | Commercial Services |
Avista Healthcare Public Acquisition Corp.
Avista Healthcare Public Acquisition Corp. Financial ConglomeratesFinance Avista Healthcare Public Acquisition Corp. engages in the provision of merger, share exchange, asset acquisition. It also includes stock purchase, and reorganization or similar business combination with one or more businesses. The company was founded on December 4, 2015 and is headquartered in New York, NY. | Finance |
ACP Mountain Holdings, Inc.
ACP Mountain Holdings, Inc. Financial ConglomeratesFinance ACP Mountain Holdings, Inc. functions as an investment holding private company. The company is based in Wilmington, DE. | Finance |
Avista Public Acquisition Corp. II
Avista Public Acquisition Corp. II Financial ConglomeratesFinance Avista Public Acquisition Corp. II operated as a blank check company. It was incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was founded on February 5, 2021 and is headquartered in New York, NY. | Finance |
- Bolsa de valores
- Insiders
- Charles Harwood